The Netherlands-based startup BIMINI Biotech, which focuses on oncology compounds, has secured €3 million in seed funding to support the advancement of preclinical development of its WASp modulators.
- Founded in 2019 by Digvijay Gahtory, Ger Strous, and Maurits Nieuwboer, BIMINI Biotech is a preclinical-stage company developing small molecule therapeutics for oncology.
- The firm targets Wiskott Aldrich Syndrome Protein (WASp) to address haematological cancers and autoimmune disorders. Its modulators are designed to inhibit WASp and disrupt the growth and aggressiveness of leukaemia and lymphoma cells.
Details of the deal
- The seed round was led by Torrey Pines Investment, a San Diego-based venture capital firm that backs early-stage life science startups. InnovationQuarter Capital, Libertatis Ergo Holding, and a business angel also participated.
"We are very pleased to support the team and exciting science behind BIMINI Biotech and see this European investment as another milestone of our strategic expansion in such high-impact research areas as hematology," claims Rouslan Michtchenko, Director of Strategic Partnering and Investment.
- BIMINI Biotech will use the €3 million in funding to accelerate the preclinical development of its WASp modulators and validate their safety and efficacy.
“We are excited to welcome this experienced group of investors and have the continued support of our existing shareholders that believe in the potential of our first-in-class WASp-modulators," CEO of BIMINI Biotech, Dr. Digvijay Gahtory, stated.
